Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares IssuedShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) Long-Term Debt Issuances (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Long-Term Debt Issuances for 10 consecutive years, with $26.0 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Issuances changed N/A to $26.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $911.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $911.0 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Issuances for Q4 2025 was $26.0 million at BeOne Medicines, down from $885.0 million in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $885.0 million in Q3 2025, with the low at -$22.5 million in Q4 2023.
  • Average Long-Term Debt Issuances over 5 years is $87.7 million, with a median of $9.1 million recorded in 2024.
  • The sharpest move saw Long-Term Debt Issuances crashed 234.5% in 2024, then surged 9875.76% in 2025.
  • Over 5 years, Long-Term Debt Issuances stood at $6.0 million in 2021, then soared by 520.9% to $37.4 million in 2022, then plummeted by 160.21% to -$22.5 million in 2023, then surged by 59.77% to -$9.1 million in 2024, then soared by 387.2% to $26.0 million in 2025.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods came in at $26.0 million, $885.0 million, and -$9.1 million for Q4 2025, Q3 2025, and Q3 2024 respectively.